Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 3/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.40 |
| ▸ | HRH1 | P35367 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6097921 | 0.95 | HRH3 (0.40) | MCL1HRH3HRH1MEN1HTR2C | |
| SCHEMBL6097126 | 0.85 | MCL1 (0.43) | MCL1HRH3HRH1MAPTHTT | |
| SCHEMBL6202054 | 0.77 | HRH3 (0.40) | MCL1HRH3HRH1HTR2CMAPT | |
| SCHEMBL6097732 | 0.75 | SMN1; SMN2 (0.45) | MCL1MEN1HTTDRD2DRD3 | |
| SCHEMBL6097603 | 0.74 | MAPT (0.41) | HRH3MEN1HTR2CMAPTHTT | |
| SCHEMBL6099897 | 0.70 | KDM4E (0.41) | HRH3MEN1HTR2CMAPTHTT | |
| SCHEMBL6098861 | 0.70 | HIF1A (0.43) | MEN1HTR2CMAPTHTTHTR1A | |
| SCHEMBL6098655 | 0.70 | MCL1 (0.41) | MCL1 | |
| SCHEMBL9097701 | 0.65 | LTA4H (0.66) | HRH3HRH1MEN1MAPTHTR1A | |
| SCHEMBL10227920 | 0.64 | MAPT (0.45) | HTR2CMAPTDRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7022694-B2 | Indoles and indolines having 5-HT activity | PHARMACIA & UPJOHN COMPANY (US) | 2006-04-04 | — | — | US | claimed |
| EP-1406902-B1 | HEXAHYDROAZEPINO[4,5-G]INDOLES AND INDOLINES AS 5-HT RECEPTOR LIGANDS | PHARMACIA & UPJOHN CO LLC (US) | 2005-10-19 | — | — | EP | claimed |
| US-20030060458-A1 | Indoles and indolines having 5-HT activity | PHARMACIA & UPJOHN COMPANY | 2003-03-27 | — | — | US | claimed |
| US-20150238506-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2015-08-27 | — | — | US | disclosed |
| US-20150238506-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2015-08-27 | — | — | US | disclosed |
| US-9079907-B2 | Fused heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-07-14 | — | — | US | disclosed |
| US-9079907-B2 | Fused heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-07-14 | — | — | US | disclosed |
| EP-2018863-B9 | Fused heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL (JP) | 2015-02-18 | — | — | EP | disclosed |
| EP-2789338-A2 | Condensed pyridine derivate and use thereof | Takeda Pharmaceutical Company Limited (JP) | 2014-10-15 | — | — | EP | disclosed |
| EP-2018863-B1 | Fused heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL (JP) | 2014-08-13 | — | — | EP | disclosed |
| EP-2742936-A1 | Fused heterocyclic compound and use thereof | Takeda Pharmaceutical Company Limited (JP) | 2014-06-18 | — | — | EP | disclosed |
| US-20090131402-A1 | Fused heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-05-21 | — | — | US | disclosed |
| US-20070274913-A1 | Preventives/Remedies for Stress Urinary Incontinence and Method of Screening the Same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-11-29 | — | — | US | disclosed |
| US-20070274913-A1 | Preventives/Remedies for Stress Urinary Incontinence and Method of Screening the Same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-11-29 | — | — | US | disclosed |
| EP-1792629-A1 | PREVENTIVES/REMEDIES FOR STRESS URINARY INCONTINENCE AND METHOD OF SCREENING THE SAME | Takeda Pharmaceutical Company Limited (JP) | 2007-06-06 | — | — | EP | disclosed |
| US-7022694-B2 | Indoles and indolines having 5-HT activity | PHARMACIA & UPJOHN COMPANY (US) | 2006-04-04 | — | — | US | disclosed |
| EP-1406902-B1 | HEXAHYDROAZEPINO[4,5-G]INDOLES AND INDOLINES AS 5-HT RECEPTOR LIGANDS | PHARMACIA & UPJOHN CO LLC (US) | 2005-10-19 | — | — | EP | disclosed |
| EP-1406902-A1 | HEXAHYDROAZEPINO(4,5-G)INDOLES AND INDOLINES AS 5-HT RECEPTOR LIGANDS | PHARMACIA & UPJOHN COMPANY (US) | 2004-04-14 | — | — | EP | disclosed |
| US-20030060458-A1 | Indoles and indolines having 5-HT activity | PHARMACIA & UPJOHN COMPANY | 2003-03-27 | — | — | US | disclosed |
| WO-2003006466-A1 | HEXAHYDROAZEPINO (4, 5-G) INDOLES AND INDOLINES AS 5-HT RECEPTOR LIGANDS | PHARMACIA & UPJOHN COMPANY (US) | 2003-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131402-A1 | Fused heterocyclic compound and use thereof | HTR2C, HTR3C, HTR3B | MCL1 3564/4885HRH3 462/4885HRH1 546/4885 |
| US-20030060458-A1 | Indoles and indolines having 5-HT activity | TPH1, HTR5A, TPH2 | MCL1 2096/4885HRH3 142/4885HRH1 161/4885 |
| US-20070274913-A1 | Preventives/Remedies for Stress Urinary Incontinence and Method of Screening the Same | ADRA2C, HTR2C, HTR3A | MCL1 4882/4885HRH3 958/4885HRH1 613/4885 |
| US-20150238506-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | HTR2C, HTR3C, HTR3B | MCL1 3564/4885HRH3 462/4885HRH1 546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.